Prenetics / DNAFit Acquire Oxsed (Oxford University Spin-out)
October 28, 2020
Hong Kong-based Prenetics, via its UK entity DNAFit Life Sciences Limited, has acquired Oxsed, an Oxford University spin-out that developed a rapid RT-LAMP COVID-19 testing platform. The acquisition gives DNAFit/Prenetics exclusive global rights to the Oxsed technology to accelerate R&D, scale manufacturing and deploy rapid point-of-care testing (including airport trials) worldwide.
- Buyers
- DNAFit Life Sciences Limited, Prenetics Limited
- Targets
- Oxsed
- Industry
- Medical Devices
- Location
- England, United Kingdom
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
WuXi AppTec Completes Acquisition of OXGENE
March 2, 2021
Biotechnology
WuXi AppTec, via its cell and gene therapy unit WuXi Advanced Therapies (WuXi ATU), completed the acquisition of Oxford-based OXGENE on March 2, 2021. The purchase brings OXGENE's gene-therapy discovery and viral-vector manufacturing technologies into WuXi ATU, expanding its capabilities and establishing its first European facility to better serve global cell and gene therapy customers.
-
Eurofins Scientific Acquires Majority Stake in LifeCodexx
July 27, 2017
Biotechnology
Eurofins Scientific has acquired a 62.63% stake in LifeCodexx AG from GATC Biotech AG, strengthening Eurofins' non-invasive prenatal testing (NIPT) capabilities. LifeCodexx, headquartered in Constance, Germany, is a developer of the PrenaTest NIPT and generated approximately EUR 7m in revenue in 2016.
-
P4 Diagnostix Acquires Assets of Strand Diagnostics (know error)
February 11, 2020
Healthcare Services
P4 Diagnostix announced the acquisition of the assets of Strand Diagnostics, the creator of the know error DNA specimen provenance testing system. P4 said it will resume testing, supplies and logistics for know error clients and immediately offer Strand's UroSeq assay to expand P4's molecular testing capabilities for urology and oncology customers.
-
Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)
October 4, 2022
Biotechnology
Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.
-
R-Biopharm AG Acquires AusDiagnostics
June 7, 2022
Biotechnology
German biotechnology company R-Biopharm AG has acquired Australian molecular diagnostics manufacturer AusDiagnostics. The purchase adds AusDiagnostics' multiplex MT-PCR platforms, extraction reagents and laboratory automation capabilities to R-Biopharm's clinical diagnostics portfolio, supporting capability expansion and internationalization into new clinical, veterinary and applied testing markets.
-
Praesidian Capital Acquires Undisclosed Genetics Business
September 18, 2019
Healthcare Services
Praesidian Capital announced the acquisition of an integrated clinical and laboratory services company operating in genetic medicine, focused on prenatal and preconception testing and hereditary cancer risk assessments. The deal is Praesidian’s first as an independent sponsor and will serve as a platform for national expansion and future add-on acquisitions.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.